|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, long-term interference with the NPY system to target obesity or cancer related aspects needs to consider potential side effects on bone health.
|
21439311 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, moderate down-regulation of NPY did not affect basal feeding or normal body weight gain but the response to food deprivation was compromised since fasting-induced hyperphagia was inhibited and fasting-induced decrease in locomotor activity was absent.These results highlight the importance of the physiological ARC NPY levels oscillations on feeding regulation, fasting response and body weight preservation, and are important for the design of therapeutic interventions for obesity that include the NPY.
|
21799827 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both overexpression of agouti-related peptide or neuropeptide Y in the paraventricular nucleus or lateral hypothalamus induce obesity in a neuropeptide- and nucleus specific manner.
|
21211526 |
2011 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the role of two functional NPY polymorphisms, NPY-Leu7Pro (rs16139) and NPY-399C/T (rs16147) and obesity for the development of asthma as well as atherosclerosis in asthmatic and non-asthmatic subjects.
|
23122776 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we sought to determine whether the effects of NPY on feeding and/or obesity are dissociable from effects on hepatic VLDL-TG secretion.
|
23074243 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results provide evidence that the functionally relevant SNP in the NP-Y promoter gene affects body fat distribution and serum leptin levels in women, pointing towards possible behavioral effects of NPY in obesity.
|
23652383 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The objective of the present study was to evaluate the association of single nucleotide polymorphisms (SNPs) in the NPY gene with obesity, metabolic syndrome features, and inflammatory and cardiovascular disease (CVD) risk biomarkers in Spanish children.
|
23624317 |
2013 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that NPY mRNA expression was higher in obese than in normal weight humans (p<0.05) in both subcutaneous and visceral adipose tissues and was significantly greater in visceral when compared with subcutaneous fat in overall (p<0.01), obese (p<0.05) and normal weight humans (p<0.05).
|
23838112 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, upregulation of NPY may have an impact in anti-cancer treatment of neuroblastomas with VPA, and antagonizing hypothalamic NPY effects may help to ameliorate VPA-induced weight gain and obesity without interfering with the desired central effects of VPA.
|
23994577 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) is a neurotransmitter and enhances the development of obesity and other aspects of MetS.
|
22308535 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These studies underscore the potential of (pGlu-Gln)-CCK-8 for the treatment of obesity-diabetes and suggest modulation of NPY and melanocortin related pathways may be involved in the observed beneficial effects.
|
23315994 |
2013 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Because NPY is a potent orexigenic peptide stimulating food intake, and genetic variation of the gene has been shown to influence development of obesity, we investigated the impact of NPY polymorphisms on antipsychotic-induced BWG.We analyzed 5 polymorphisms in the NPY gene (rs10551063, rs16147, rs5573, rs5574, and rs16475) in schizophrenia subjects (n = 226), treated mostly with clozapine and olanzapine for up to 14 weeks.
|
23277265 |
2013 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Data were extracted and summary estimates of the association between the NPY variants and obesity were examined.
|
26240981 |
2015 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The objective was to examine the effects of NPY variant rs16147 on central obesity and abdominal fat distribution in response to dietary interventions.
|
26156739 |
2015 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
While in heterozygous mice the adipogenic effect of NPY is important, in homozygous mice inhibition of sympathetic tone leading to decreased lipolytic activity and impaired brown fat function, as well as increased endocannabinoid levels contribute to obesity.
|
26681068 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Few genes such as leptin, leptin receptor encoded by the db (diabetes), pro-opiomelanocortin, AgRP and NPY and melanocortin-4 receptors and insulin-induced gene 2 were linked to obesity.
|
27623943 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
To identify NPY gene-by-stress interaction effects on human obesity, we analyzed the interaction between four NPY SNPs and stress with obesity-related traits, including visceral adipose tissue (VAT).
|
27010740 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In obese males, the rs164147 polymorphism of the NPY gene is associated with leptin, insulin level, HOMA-IR, and an increased risk of MetS and its related phenotypes, such as central obesity and hyperglycemia.
|
27788523 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
No significant interaction between NPY SNP polymorphisms and obesity were detected.
|
27469060 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These data illustrate that mild cold stress is a critical factor preventing the development of obesity in Snord116<sup>-/-</sup> mice via the NPY system.
|
27823858 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y (NPY) Y<sub>4</sub> receptor (Y<sub>4</sub>R) is involved in energy homeostasis and considered a potential drug target for the treatment of obesity.
|
28345900 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Loss of neuropeptide Y (NPY) can correct the obesity syndrome of mutant mice lacking of leptin (ob/ob).
|
28864114 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Similarly, mice overexpressing NPY in noradrenergic neurons (OE-NPY<sup>DBH</sup>) display obesity and impaired glucose metabolism.
|
28468933 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because NPY and pporexin are negatively regulated by leptin, these findings suggest that in the intrauterine growth restriction group, the leptin resistance of hypothalamic functions, which is usually caused by diet-induced obesity in adulthood, had already been established in the peri-pubertal period.
|
28321032 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Considering that chronic obesity decreases ArcN NPY content, we propose that the ArcN NPY neuropathway to the PVN and DMH is pivotal in obesity-induced elevations in SNA.
|
28628036 |
2017 |